Democritus University of Thrace (DUTH)
Μελέτη του ρόλου των Τ ρυθμιστικών λεμφοκυττάρων στην παθογένεια των διαμέσων πνευμονοπαθειών
Abstract
dc:descriptionINTRODUCTION: The term interstitial lung diseases encompasses a heterogeneous group of restrictive lung diseases with pulmonary fibrosis as the common point. Idiopathic pulmonary fibrosis (IPF) is a progressive, devastating fibrotic diffuse parenchymal disease which often culminates to a fatal outcome 3-5 years after diagnosis, regardless of treatment. While the molecular mechanisms underlying IPF pathogenesis are still elusive and controversial its incidence is constantly rising and is estimated at 5 million cases all over the world where 40.000 cases die every year. As regards the involvement of T lymphocytes in IPF, data are largely conflicting and support either a profibrotic or antifibrotic role of the former in pulmonary fibrosis. Nevertheless, most of the above studies investigated T cells as a whole, whereas the emerging novel subpopulations of effector and regulatory T cells may have antithetical actions in IPF, thus reconciling the incongruous findings. Such a subpopulation, the CD4+CD25+FOXP3+ Τ regulatory cells (Tregs), is essential for the control of the immunologic tolerance and the prevention of autoimmunity. Considering the central role of Tregs in immune regulation, we sought to explore Treg dynamics and function in IPF, by studying BAL and PB Tregs in normal donors and patients with IPF or other lung diseases. In addition, patients with collagen vascular diseases with pulmonary parenchymal involvement (CVD-IP) served as “positive” controls for Treg dysfunction, as these disorders are largely characterized by Treg defects. PATIENTS & METHODS: Treg number,frequency and CXCR3 expression was assessed by 4-color flow cytometry in the peripheral blood (PB) and bronchoalveolar lavage (BAL) of healthy volunteers (HV, n=28), patients with IPF ( n=21), patients with CVD-IP (n=18) and other lung diseases besides IPF patients (non-IPF,n=35). Treg suppressor activity was assessed by proliferation and suppression assays of MACS-isolated PB and BAL Tregs after polyclonal stimulation with plate bound CD3/CD28 Dynabeads. The levels of cytokines IFN-γ, TNF-α, IL-4 and IL-10 were measured in the supernatants of the proliferation assays described above by using the Human Th1/Th2 Cytokine cytometric bead array Kit, whereas TGF-β secretion by polyclonally stimulated Tregs was assessed by ELISA. The significance of the differences was assessed by one way ANOVA or paired Student’s t test as appropriate and the results are presented as mean ± SEM. Correlations were assessed with Spearmans rank test. RESULTS: A twofold reduction in the percentage of Tregs was observed in the BAL of IPF patients, compared to nIPF and CVD-IP patients. Furthermore, although not statistically significant, the absolute Treg cell number/L in IPF was substantially lower than in nIPF and CVD-IP. In PB, patients with IPF showed significantly lower percentage of CD4+CD25+FOXP3+ Tregs compared to the rest of the groups. Similarly, the absolute number of Tregs in the PB of IPF patients was nearly the half of the respective in the PB of HV, nIPF and CVD-IP patients. Treg percentage and absolute count in either cellular compartment did not differ significantly among nIPF, CVD-IP patients and healthy volunteers. Treg percentage and absolute number in PB of 4 IPF patients remained unaltered before and after steroid administration and antioxidants for six months. Tregs from BAL as well as PB were considerably less efficient in suppressing autologous polyclonal T cell proliferative responses in IPF patients compared to HV and nIPF patients. Likewise, the suppressive capacity of Tregs from CVD-IP patients was up to three times lower, although not always statistically significant, compared to HV and nIPF patients. In contrast, both BAL and PB Tregs in CVD-IP exhibited comparable suppression to the IPF ones. Τhe determination of Treg-induced inhibition of IFN-γ and TNF-α production in the supernatants of proliferation assays, yielded comparable results with the in vitro inhibition of Teff proliferation, as BAL Tregs from IPF patients failed to adequately suppress IFN-γ, TNF-α and IL-4 secretion compared to those of HV and nIPF patients. Comparable CXCR3 levels were observed in PB CD4+ cells of IPF, nIPF and CVD-IP patients and HV. By contrast, CXCR3 expression on PB Tregs was increased in IPF compared to HV and nIPF patients, whereas CVD-IP patients had also higher, but not statistically significant, CXCR3 levels in PB Tregs than HV and nIPF. Conversely, in BAL, both Tregs and total CD4+ cells showed significantly reduced CXCR3 expression in IPF patients compared to nIPF patients. Consistent to the findings in PB Tregs, CXCR3 in CVD-IP BAL Tregs was equally expressed with IPF and quite lower than nIPF Tregs. CONCLUSIONS: In conclusion, the present study provides the first evidence of a local and systemic dysfunction of Tregs in IPF. Treg deficiency is severe, as Tregs are not only numerically deficient, but also of dysfunctional at the single cell level while the deficiency is more prominent in the lung tissue, implying a link between Treg impairment and pulmonary fibrosis. In addition, the strong correlation of the compromised Treg function in BAL with parameters of disease severity further supports this notion. Thus, Tregs emerge as the first regulatory T cell subpopulation that may contribute to the pathogenesis of IPF and render Tregs as candidate targets for a cell-based therapy of this incurable disease.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Nakou, Evangelia
- Νάκου, Ευαγγελία
Subjects
dc:subject × 9Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/26962